KOD logo

KODIAK SCIENCES INC

KODNASDAQ
🏆 #1227 by market capEarnings Nov 11US Equity
$91.16▲ $1.27 (+1.39%)
After hours · at close
🔔
Track KOD
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 1.4%
7d▲ 169.5%
14d▲ 176.2%
30d▲ 141.4%
ytd▲ 226.2%
1y▲ 476.1%
🏦Market Cap
$5.70B
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
56
Weak

Trading Snapshot

Day Range
$90.15 – $92.84
52-Week Range
$10.94 – $95.77
Volume
$5.47B
Avg Volume
$7.01B
Shares Outstanding
62.6M
Next Earnings
Dec 12, 2026

Fundamentals Snapshot

Annual Revenue
$704M
Last Q Revenue
$189M
P/E Ratio
-21.5
P/S Ratio
0.0x
EPS (TTM)
$-3.86
Dividend Yield
0.00%
Dilution (1yr)
+1.1%

Why Investors Own KOD

  • ✓High-growth profile — revenue up -7.3% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 60% gross margin and 12% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

KOD logo

KODIAK SCIENCES INC

KOD
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$234M▲ +25.4% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$137M▲ +16.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
53.2M▲ +1.1% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$51M▼ −$47M YoY
StockOtter · stockotter.space

About KODIAK SCIENCES INC

Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
56/100

Analyst Ratings

ⓘ
Consensus
Buy
10 analysts
Strong Buy2
Buy7
Hold1
Sell0
Strong Sell0
Ratings as of Sep 2026

Latest News & Updates

🚀
CNBC·2h ago

KODIAK SCIENCES INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
MarketWatch·5h ago

Analysts lift KOD price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Bloomberg·1d ago

KODIAK SCIENCES INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.